Cité-Farma SA
Cité-Farma reported total assets of 681,065 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Sep 2026).
The score of Cité-Farma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +59 % Total assets +20 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Cité-Farma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 65,680 € | ||||
| Equity | 485,714 € | ||||
| Cash | 282,588 € | ||||
| EBITDA | 104,587 € | ||||
| Total assets | 681,065 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Sep 2026
- Year ended 31 Dec 2024filed on 30 Sep 2025
- Year ended 31 Dec 2023filed on 11 Dec 2024
- Year ended 31 Dec 2022filed on 29 Sep 2023
- Year ended 31 Dec 2021filed on 23 Dec 2022
Cité-Farma's financial analysis
- Solvency71.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Cité-Farma
Cité-Farma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0414.311.942
- VAT number
- BE0414311942
- Peppol
- Registered · 0208:0414311942 · as of 11 Nov 2026
- Legal form
- SA
- Incorporated
- 01 Jan 1974
- Registered office
- 3550 Heusden-Zolder
- Latest accounts
- 2025 · filed on 30 Sep 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Cité-Farma (SA) has been based in Heusden-Zolder since 1974, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 65,680 € and equity of 485,714 €; its revenue is not published. Its solvency stands at 71.3%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Cité-Farma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie des Trieux Retail sale of pharmaceutical products Fontaine-l'Évêque · balance sheet 681,455 €
- Apotheek Defauw Frank Retail sale of pharmaceutical products Roeselare · balance sheet 680,611 €
- Pharm-OZ Retail sale of pharmaceutical products Charleroi · balance sheet 681,585 €
- Hinnoya Retail sale of pharmaceutical products Tournai · balance sheet 680,362 €
- Laivaphar Retail sale of pharmaceutical products Tienen · balance sheet 679,253 €
- Pharmaldeia Retail sale of pharmaceutical products Ghent · balance sheet 683,646 €
- Apobel Retail sale of pharmaceutical products Zottegem · balance sheet 683,671 €
- 3Spharma Retail sale of pharmaceutical products Lubbeek · balance sheet 690,815 €
Frequently asked questions about Cité-Farma
What is the revenue of Cité-Farma?
Cité-Farma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Cité-Farma?
In Belgium, the VAT number is the company number prefixed with BE: BE0414311942 for Cité-Farma, if the company is VAT-registered. Its company number (CBE) is 0414.311.942.
Where is the registered office of Cité-Farma?
According to the CBE register, the registered office of Cité-Farma is in 3550 Heusden-Zolder.
What is the equity of Cité-Farma?
At the close of the 2025 financial year, the equity of Cité-Farma amounts to 485,714 €, a solvency of 71.3% of total assets.
Who manages Cité-Farma?
The register lists 5 active mandates at Cité-Farma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Cité-Farma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →